Apogee Therapeutics (NASDAQ:APGE – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.60) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.60), Yahoo Finance reports.
Apogee Therapeutics Stock Performance
Apogee Therapeutics stock opened at $44.41 on Wednesday. The company has a market cap of $2.60 billion and a P/E ratio of -8.46. Apogee Therapeutics has a one year low of $14.19 and a one year high of $72.29. The business has a fifty day moving average of $43.02 and a two-hundred day moving average of $47.60.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the company. Wedbush reaffirmed an “outperform” rating and set a $87.00 price objective on shares of Apogee Therapeutics in a research report on Monday, May 13th. Bank of America assumed coverage on Apogee Therapeutics in a report on Friday, May 10th. They set a “buy” rating and a $80.00 price target for the company. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $73.00.
Insider Transactions at Apogee Therapeutics
In related news, insider Carl Dambkowski sold 7,335 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $40.67, for a total transaction of $298,314.45. Following the sale, the insider now owns 287,458 shares of the company’s stock, valued at $11,690,916.86. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 40,000 shares of the company’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $40.62, for a total value of $1,624,800.00. Following the sale, the chief executive officer now owns 1,434,487 shares of the company’s stock, valued at $58,268,861.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Carl Dambkowski sold 7,335 shares of Apogee Therapeutics stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $40.67, for a total value of $298,314.45. Following the transaction, the insider now directly owns 287,458 shares of the company’s stock, valued at approximately $11,690,916.86. The disclosure for this sale can be found here. Insiders have sold a total of 68,330 shares of company stock valued at $2,707,426 in the last ninety days. 36.10% of the stock is currently owned by company insiders.
Apogee Therapeutics Company Profile
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Recommended Stories
- Five stocks we like better than Apogee Therapeutics
- Canadian Penny Stocks: Can They Make You Rich?
- Chipotle Mexican Grill: Take a Bite of This Smoking Hot Deal
- Golden Cross Stocks: Pattern, Examples and Charts
- Why O’Reilly Automotive Stock Could Be a Long-Term Winner
- What is a Special Dividend?
- Hut 8 Corp.’s Earnings: Is Crypto Mining About to Change?
Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.